 Silodosin received its first marketing approval in Japan in May 2006 under the tradename "Urief", which is jointly marketed by Kissei Pharmaceutical and Daiichi Sankyo.Kissei licensed the US, Canadian, and Mexican rights for silodosin to Watson Pharmaceuticals in 2004.The FDA approved silodosin on 9 October 2008 as "Rapaflo".